• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-1

tetano

Editor, Senior Moderator
Cell Rep Med


. 2022 May 17;100651.
doi: 10.1016/j.xcrm.2022.100651. Online ahead of print.
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents


Pablo Garcia-Valtanen[SUP] 1 [/SUP], Christopher M Hope[SUP] 2 [/SUP], Makutiro G Masavuli[SUP] 1 [/SUP], Arthur Eng Lip Yeow[SUP] 1 [/SUP], Harikrishnan Balachandran[SUP] 3 [/SUP], Zelalem A Mekonnen[SUP] 1 [/SUP], Zahraa Al-Delfi[SUP] 1 [/SUP], Arunasingam Abayasingam[SUP] 3 [/SUP], David Agapiou[SUP] 3 [/SUP], Alberto Ospina Stella[SUP] 4 [/SUP], Anupriya Aggarwal[SUP] 4 [/SUP], George Bouras[SUP] 5 [/SUP], Jason Gummow[SUP] 6 [/SUP], Catherine Ferguson[SUP] 7 [/SUP], Stephanie O'Connor[SUP] 8 [/SUP], Erin M McCartney[SUP] 7 [/SUP], David J Lynn[SUP] 9 [/SUP], Guy Maddern[SUP] 10 [/SUP], Eric J Gowans[SUP] 1 [/SUP], Benjamin A J Reddi[SUP] 8 [/SUP], David Shaw[SUP] 7 [/SUP], Chuan Kok-Lim[SUP] 11 [/SUP], Michael R Beard[SUP] 12 [/SUP], Daniela Weiskopf[SUP] 13 [/SUP], Alessandro Sette[SUP] 14 [/SUP], Stuart G Turville[SUP] 4 [/SUP], Rowena A Bull[SUP] 3 [/SUP], Simon C Barry[SUP] 15 [/SUP], Branka Grubor-Bauk[SUP] 16 [/SUP]



Affiliations

Abstract

Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs.

Keywords: SARS-CoV-2; T cell immunity; Variant of Concern; antibody response; antigen drift; memory B cells; virus neutralization.
 
Back
Top Bottom